Bausch Health Companies Inc. · TSX:BHC
Bausch Health Companies — Biovail Corp International — Investor Presentation (July 2005)
13 slides from Bausch Health Companies's investor presentation, Jul 22, 2005
Slide 1: Biovail at a Glance
BIOVAIL AT A GLANCE Biovail Corporation is a technology-rich specialty pharmaceutical company specializing in the development, manufacture, sale and marketing of controlled-release medications for the treatment of chronic medical conditions. Biovail’s core strategy is to apply its world-leading drug
Slide 2: Biovail's facilities and operations
Bio's ach in Chany, Vig, an Fb spprved manutcting ste pent ecb. rante setts Bisa emollient) Lines ie cemented ote deeopant of rove li Lateran teins! SRL ea age ties pharmacatn famultin Opera n hugiet 2009, Slavs 52,000-2nae ot ned tenn Museau, Ovi, he ie fer many et te Company compat pets, 5 wel 6 B
Slide 3: Biovail's Drug-Delivery Technologies
BIOVAIL’S DRUG-DELIVERY TECHNOLOGIES Without question, Biovail’s core competencies originate in drug-delivery technologies. Biovail has a broad portfolio of oral drug-delivery technology platforms, which are applied to existing in-market drugs to develop enhanced formulations that provide clinically
Slide 4: Drug microsphere mounted on the head of a pin
Drug microsphere mounted on the head of a pin.
Slide 5: Our Markets
Through our development efforts, Biovail continues to focus on providing pharmaceutical products to address existing and unmet primary-care patient needs in the United States – the world’s largest pharmaceutical market. OUR MARKETS Biovail’s primary markets include the United States, the world’s lar
Slide 6: Slide 6
Slide 7: Central Nervous System Disorders
As a front-line treatment for depressive illnesses in adults, Wellbutrin XL ® has been well received by physicians in the United States, capturing 54.8% of all bupropion prescriptions in 2004. Central Nervous System Disorders Biovail’s commercial portfolio of central nervous system (CNS) products cu
Slide 8: Wellbutrin XL and GSK supply agreement
Launched in September 2003 by our marketing partner GlaxoSmithKline (GSK), Wellbutrin XL®, an extended-release formulation of bupropion indicated as first-line therapy for the treatment of depression, has been well received by U.S. physicians, and at the end of 2004, had captured 54.8% of all buprop
Slide 9: Slide 9
Slide 10: Pain Management
Biovail’s pain-management franchise is anchored by extended-release and orally disintegrating tablet formulations of tramadol. Pain Management Pain management is another therapeutic area of focus for Biovail. The Company’s emerging pain franchise includes Tramadol ODT – an orally disintegrating tabl
Slide 11: Biovail Products
BIOVAIL PRODUCTS The following table summarizes Biovail’s 2004 commercial portfolio: PRODUCT THERAPEUTIC AREA INDICATION(S) THERAPEUTIC MARKET SIZE* PROMOTED PRODUCTS U.S. CARDIZEM ® LA (1) CARDIOVASCULAR HYPERTENSION / ANGINA $ 16.2 BILLION TEVETEN ® (2) CARDIOVASCULAR HYPERTENSION $ 16.2 BILLION T
Slide 12: Product Pipeline
Biovail believes that its product pipeline is among the deepest in the specialty pharmaceuticals industry, with over 25 programs under development. PRODUCT PIPELINE Biovail is working to develop clinically enhanced, branded versions of a number of existing in-market pharmaceutical compounds. In 2004
Slide 13: More Information?
MORE INFORMATION? INVESTOR RELATIONS 905.286.3000 IR@BIOVAIL.COM
Biovail Corp International — Investor Presentation (July 2005) on 6ix